Imaging molecular signatures in oligodendroglioma

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7109-7111

  Cairncross, J Gregory ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; FLUORODEOXYGLUCOSE F 18; LOMUSTINE; METHIONINE C 11; NITROSOUREA DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; THALLIUM 201; VINCRISTINE;

BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; NEUROIMAGING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT;

ALLELES; BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; MITOSIS; OLIGODENDROGLIOMA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 8444224572     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2018     Document Type: Note

References (19)

1. Walker C, du Plessis DG, Fildes D, et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 2004;10:7182-91
2. Kashten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-85.
3. Giammarile F, Cinotti LE, Jouvet A, et al. High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neuro-Oncol 2004;68:263-74.
4. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90.
5. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organiztion for Research and Treatment of Cancer 22845 with the Medical Research Council study BR04-an interim analysis. Int J Radiat Oncol Biol Phys 2002;52:316-24.
6. Cairncross JG, Macdonald DR. Successful chemotherapy for malignant oligodendroglioma. Ann Neurol 1988;23:360-4.
7. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573-4.
8. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001;19:2449-55.
9. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-8.
10. Cairncross JG, Seiferheld W, Shaw E, et al. An intergroup randomized controlled clinical trial (RTC) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02. Proc Am Soc Clin Oncol 2004;23:107.
11. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (Bethesda) 1998;90:1473-9.
12. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;43:825-30.
13. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45.
14. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45.
15. Betensky R, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002;20:2495-9.
16. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003;62:111-26.
17. Zlatescu MC, Tehrani Yazdi AR, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713-5.
18. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-9.
19. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of genetic signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303-6.